CARLSBAD, Calif., Nov. 14 /PRNewswire-FirstCall/ -- iVOW, Inc. , a provider of disease management services for the treatment of chronic and morbid obesity, today reported financial results for the third quarter ended September 30, 2005.
For the quarter ended September 30, 2005, the Company reported a net loss of $504,000, or $(0.13) per basic and diluted share, on revenues of $320,000, versus a net loss of $837,000, or $(0.80) per basic and diluted share, on revenues of $375,000, for the corresponding quarter of 2004. The $333,000 lower net loss for the quarter ended September 30, 2005 was the result of cost reduction efforts in product development, sales and marketing and general and administrative costs.
For the nine months ended September 30, 2005, iVOW reported a net loss of $1,947,000, or $(1.27) per share on revenues of $812,000, compared with a net loss of $2,535,000, or $(3.47) per share on revenues of $1,277,000 for the same period of 2004. Included in the reported net loss for the three and nine months ended September 30, 2005 was a gain from discontinued operations of $75,000, or $0.04 per basic and diluted share, and $208,000, or $0.15 per basic and diluted share, respectively, compared to a loss from discontinued operations of $0.00 per basic and diluted share, and $633,000, or $(0.79) per basic and diluted share, respectively, for the same periods in 2004.
Dr. Michael Owens, President and CEO of iVOW, said, "Our VOW center model continues to trend in a positive direction, as our revenues increased 26% over the previous quarter. This is attributable to increased contributions from our consulting products on top of the management fees from our iVOW Centers.
"Shortly after the quarter, we also took an important step in the evolution of iVOW with the acquisition of Sound Health Solutions. With this acquisition, we have added a highly respected medical treatment model to our bariatric surgical model, and better aligned our company with the emerging treatment approaches for obesity. We now have a more comprehensive service approach that will allow our long-term growth opportunities to be considerably less constrained by the reimbursement environment for bariatric surgery," said Dr. Owens.
Conference Call and Webcast
iVOW will hold a conference call with simultaneous webcast on Monday, November 14th at 12:00 p.m. Eastern/9:00 a.m. Pacific. The conference call will feature Dr. Michael Owens, President and Chief Executive Officer, and Brad Hanson, Chief Financial Officer, in a discussion of third quarter results and events. Members of the public are invited to listen through the Investor Relations section of the Company's web site, www.iVOW.com. The dial-in number for the conference call is (800) 240-4186.
To be added to iVOW's investor e-mail or fax lists, contact Tony Rossi via e-mail at email@example.com or via phone at 310-854-8317.
Our business is focused exclusively on the disease state management of chronic and morbid obesity. We provide program management, operational consulting and clinical training services to physicians and hospitals involved in the medical and surgical treatment of morbidly obese patients. We also provide specialized vitamins to patients who have undergone obesity surgery. Our corporate website is www.ivow.com; information on our nutritional supplements for post-surgical gastric bypass patients may be found on www.vistavitamins.com. iVOW is the new corporate name of Vista Medical Technologies, Inc. iVOW is traded on the NASDAQ Capital Market under the stock symbol IVOW.
Forward Looking Statements
This news release may contain forward-looking statements concerning the business and products of IVOW, inc. Actual results may differ materially depending on a number of risk factors, including, but not limited to the following: the Company's ability to penetrate the market for obesity surgery management services; the impending decision by Medicare on coverage for bariatric surgery and the Company's ability to successfully integrate the business and operations of Sound Health Solutions, Inc. Other risks inherent in our business are described in the Company's Securities and Exchange Commission filings, including its Quarterly Report on Form 10-QSB for the nine-month period ended September 30, 2005. The Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
FOR FURTHER INFORMATION
AT iVOW: AT FINANCIAL RELATIONS BOARD:
Michael H. Owens, MD, MPH, FACPE, CPE Tony Rossi
President & CEO Media Contact
(760) 603-9120 (310) 854-8317
Condensed Statements of Operations and Comprehensive Loss
Three Months Ended Nine Months Ended
September 30, September 30,
2005 2004 2005 2004
Revenues $319,575 $374,777 $812,172 $1,277,492
Costs and expenses:
Cost of revenues 289,739 217,583 812,768 849,697
Product development 11,750 96,376 112,153 275,341
Sales and marketing 179,347 352,165 668,137 772,803
administrative 431,747 506,197 1,398,003 1,246,086
and expenses 912,583 1,172,321 2,991,061 3,143,927
Loss from operations (593,008) (797,544) (2,178,889) (1,866,435)
(expense), net 13,559 (39,064) 23,770 (36,292)
operations (579,449) (836,608) (2,155,119) (1,902,727)
Gain (loss) from
operations 75,000 -- 207,645 (632,516)
Net loss (504,449) (836,608) (1,947,474) (2,535,243)
preferred stock (31,933) (32,865) (67,170) (103,057)
accreted 306,512 -- 306,512
stock -- -- -- (131,985)
stockholders $(229,870) $(869,473) $(1,708,132) $(2,770,285)
Net loss (504,449) -- (1,947,474) --
securities -- -- (479,660) --
loss $(504,449) -- $(2,427,134) --
operations $(0.17) $(0.80) $(1.42) $(2.68)
operations 0.04 -- 0.15 (0.79)
Net loss per common
share applicable to
common stockholders $(0.13) $(0.80) $(1.27) $(3.47)
Shares used in
and diluted loss
per share 1,839,184 1,090,587 1,350,578 797,305
Selected Condensed Balance Sheet Data
September 30, December 31,
Cash and cash equivalents $2,200,273 $1,969,561
Total current assets 2,844,213 2,646,106
Equipment, net 21,638 31,743
Total assets 3,692,851 3,984,509
Total current liabilities 741,759 751,013
Total stockholders' equity $2,951,092 $3,222,980